Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia

International Journal of Hematology

Volumn 89, Issue 5, 2009, Pages 642-648

  Kawaguchi, Tatsuya ^a,b   Hamada, Akinobu ^a   Hirayama, Chie ^a   Nakashima, Reiko ^a   Nambu, Takeru ^a   Yamakawa, Yuji ^a   Watanabe, Hiroshi ^a   Horikawa, Kentaro ^a   Mitsuya, Hiroaki ^a   Saito, Hideyuki ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Body surface area; Chronic myeloid leukemia; Imatinib; Trough level

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; BODY SIZE; BODY SURFACE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MALE; MORNING DOSAGE; MUSCLE CRAMP; MYALGIA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; RASH; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; BODY SURFACE AREA; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PHARMACOKINETICS; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67749101106     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0315-4     Document Type: Article

References (18)

1. BJ Druker M Talpaz DJ Resta B Peng E Buchdunger JM Ford 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 10.1056/NEJM200104053441401 (Pubitemid 32267972)
2. SG O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004 10.1056/NEJMoa022457 (Pubitemid 36302244)
3. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 10.1056/NEJMoa062867 (Pubitemid 44903745)
4. GD Demetri M von Mehren CD Blanke AD Van den Abbeele B Eisenberg PJ Roberts 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480 10.1056/NEJMoa020461 (Pubitemid 34879334)
5. B Peng M Hayes D Resta A Racine-Poon BJ Druker M Talpaz 2004 Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients J Clin Oncol 22 935 942 10.1200/JCO.2004.03. 050 (Pubitemid 41103606)
6. B Peng P Lloyd H Schran 2005 Clinical pharmacokinetics of imatinib Clin Pharmacokinet 44 879 894 10.2165/00003088-200544090-00001 (Pubitemid 41252840)
7. S Picard K Titier G Etienne E Teilhet D Ducint MA Bernard 2007 Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 109 3496 3499 10.1182/blood-2006-07-036012 (Pubitemid 46572540)
8. RA Larson BJ Druker FA Guilhot SG O'Brien GJ Riviere T Krahnke 2008 Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 111 4022 4028 10.1182/blood-2007-10-116475
9. A Horikoshi K Takei S Sawada 2003 Effects of lower dose of imatinib to CML patients Leuk Res 27 1167 10.1016/S0145-2126(03)00101-2 (Pubitemid 36960038)
10. SJ Park IK Choi HY Seo HJ Sung KH Park SJ Kim 2007 Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area Acta Haematol 118 219 221 10.1159/000111777 (Pubitemid 351182634)
11. Y Kanda S Okamoto T Tauchi M Kizaki K Inokuchi M Yabe 2008 Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: dose body weight matter? Am J Hematol 83 835 839 10.1002/ajh.21274
12. K Ohnishi M Nishimura J Takeuchi S Fujisawa T Nagai K Miyamura 2007 Lower dose of imatinib provides outcomes similar to the standard dose imatinib in Japanese patients with early chronic-phase CML: the interim analyses of JALSG CML202 Study Blood 110 316a
13. A Hamada H Miyano H Watanabe H Saito 2003 Interaction of imatinib mesilate with human P-glycoprotein J Pharmacol Exp Ther 30 824 828 10.1124/jpet.103.055574 (Pubitemid 37310701)
14. C Blasdel MJ Egorin TF Lagattuta BJ Druker MW Deininger 2007 Therapeutic drug monitoring in CML patients on imatinib Blood 110 1699 1701 10.1182/blood-2007-03-079871 (Pubitemid 47443991)
15. S Dulucq S Bouchet B Turcq E Lippert G Etienne J Reiffers 2008 Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia Blood 112 2024 2027 10.1182/blood-2008-03-147744
16. S Hu RM Franke KK Filipski C Hu SJ Orwick EA de Bruijn 2008 Interaction of imatinib with human organic ion carriers Clin Cancer Res 14 3141 3148 10.1158/1078-0432.CCR-07-4913
17. H Gurney M Wong RL Balleine LP Rivory AJ McLachlan JM Hoskins 2007 Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype Clin Pharmacol Ther 82 33 40 10.1038/sj.clpt.6100201 (Pubitemid 46944197)
18. ER Gardner H Burger RH van Schaik AT van Oosterom EA de Bruijn G Guetens 2006 Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib Clin Pharmacol Ther 80 192 201 10.1016/j.clpt.2006.05.003 (Pubitemid 44160695)